Sun Pharmaceutical Industries Ltd., the Mumbai, India-based pharma giant known more for its footprint in generics than in novel drug development, gained FDA approval of Ilumya (tildrakizumab-asmn) to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.